Overview

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
Phase:
PHASE2
Details
Lead Sponsor:
Teligene US
Treatments:
TL-118